Hayden Jeffreys, Joanne Mason
Cambridge Epigenetix has appointed Hayden Jeffreys as chief operating officer and Joanne Mason as vice president of biomarker discovery. Jeffreys has previously served as interim CEO of Erba Diagnostics, as well as head of corporate business development and strategy for Erba Mannheim and Lumora. He has also held senior positions at Lab21 and Gen-Probe (now part of Hologic).
Mason was previously director of sequencing and sample acquisition for Genomics England, where she managed sample collection and sequencing for the 100,000 Genomes Project. She also set up and managed an NGS core facility at Oxford University Hospitals NHS Foundation Trust. She holds a PhD from the University of Cambridge and sits on the MHRA Genomics for Diagnosis Forum, UK NEQAS for molecular genetics DNA extraction steering committee, and Genomics England sequencing advisory board.
Pat Brooks, Rebecca Galler, Keith Jones
Mission Bio has hired Pat Brooks as senior vice president of sales and sales operations, Rebecca Galler as senior vice president of marketing, and Keith Jones as senior vice president of product development.
Brooks was previously vice president of global sales and development at Cellular Dynamics International. Prior to that, he held vice president positions at Ion Torrent, Pacific Biosciences, and Affymetrix. Brooks has a master of science and a bachelor of science degree from the University of Iowa.
Galler previously was previously involved in strategic marketing for Qventus and Castlight Health. In the past, she was head of corporate strategy at Sirna Therapeutics, director of private equity at Invesco Funds Group, and vice president of marketing at Preferred Global Health. She holds an MBA from Columbia University and a BA from Barnard College.
Jones used to be senior vice president of molecular assay research and development at Verinata Health, now part of Illumina. In the past, he was vice president of molecular genetics at Affymetrix. He holds a PhD in pharmacology from Stanford University School of Medicine and undergraduate degrees in chemistry and biological sciences from the University of California, Irvine.
PerkinElmer has elected Pascale Witz to its board of directors, effective immediately. Witz most recently served as executive vice president of Sanofi's global diabetes and cardiovascular business. Prior to that, she held several leadership positions during 17 years with GE Healthcare, including president and CEO of its medical diagnostics division. Witz also currently serves on the boards of Horizon Pharma, Regulus Therapeutics, Fresenius Medical Care, Savencia, and French-American Foundation-France.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.